CDT EQUITY INC. Financing Cash Flow
CDT EQUITY INC. (CDT) reported Financing Cash Flow of $1.67 million for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-08
- CDT EQUITY INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.19M, a 68.41% decline year-over-year.
- CDT EQUITY INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $487.00K, a 91.78% decline year-over-year.
- CDT EQUITY INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.74M, a 58.65% decline year-over-year.
- CDT EQUITY INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $6.00M, a 243.86% increase year-over-year.
- CDT EQUITY INC. net cash provided by (used in) financing activities for fiscal 2023 was $10.93M, a 346.45% increase from fiscal 2022.
- CDT EQUITY INC. net cash provided by (used in) financing activities for fiscal 2022 was $2.45M.
| Period end | Net Cash Provided by (Used in) Financing Activities 2 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.19M derived: S-1 6 month − 10-Q 3 month · filed 2026-09-08 | $1.67M S-1 · filed 2026-09-08 | $3.42M derived: sum of 3 quarters · filed 2026-09-08 | $9.41M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2026-03-31 | $487.00K 10-Q · filed 2026-07-15 | $2.23M derived: sum of 2 quarters · filed 2026-09-08 | $8.22M derived: sum of 3 quarters · filed 2026-09-08 | $11.98M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2025-12-31 | $1.74M derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08 | $7.74M derived: sum of 2 quarters · filed 2026-09-08 | $11.49M derived: sum of 3 quarters · filed 2026-09-08 | $17.42M S-1 · filed 2026-09-08 | |||||
| 2025-09-30 | $6.00M derived: 10-Q 9 month − S-1 6 month · filed 2025-11-13 | $9.75M derived: sum of 2 quarters · filed 2026-09-08 | $15.68M 10-Q · filed 2025-11-13 | $19.89M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2025-06-30 | $3.76M derived: S-1 6 month − 10-Q 3 month · filed 2026-09-08 | $9.68M S-1 · filed 2026-09-08 | $13.89M derived: sum of 3 quarters · filed 2026-09-08 | $15.64M derived: sum of 4 quarters · filed 2026-09-08 | |||||
| 2025-03-31 | $5.93M 10-Q · filed 2026-07-15 | $10.14M derived: sum of 2 quarters · filed 2026-09-08 | $11.88M derived: sum of 3 quarters · filed 2026-09-08 | ||||||
| 2024-12-31 | $4.21M derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08 | $5.95M derived: sum of 2 quarters · filed 2026-09-08 | $6.07M S-1 · filed 2026-09-08 | ||||||
| 2024-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.86M 10-Q · filed 2025-11-13 | |||||||
| 2024-06-30 | $113.00K 10-Q · filed 2025-08-14 | ||||||||
| 2023-12-31 | -$414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $8.70M derived: sum of 2 quarters · filed 2025-03-28 | $8.71M derived: sum of 3 quarters · filed 2025-03-28 | $10.93M 10-K · filed 2025-03-28 | |||||
| 2023-09-30 | $9.11M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-14 | $9.12M derived: sum of 2 quarters · filed 2024-11-14 | $11.34M 10-Q · filed 2024-11-14 | $12.28M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | $11.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-14 | $2.23M 10-Q/A · filed 2024-11-14 | -$113.32M 10-Q · filed 2023-08-14 | $3.16M derived: sum of 3 quarters · filed 2024-11-14 | -$131.82M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-03-31 | $2.22M 10-Q/A · filed 2024-11-14 | -$113.53M 10-Q · filed 2023-05-15 | $3.15M derived: sum of 2 quarters · filed 2024-11-14 | -$131.84M derived: sum of 3 quarters · filed 2024-11-14 | -$131.84M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2022-12-31 | $933.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | -$134.06M derived: sum of 2 quarters · filed 2024-04-16 | -$134.06M derived: sum of 3 quarters · filed 2024-04-16 | $2.45M 10-K · filed 2024-04-16 | $136.50M 10-K · filed 2023-03-28 | ||||
| 2022-09-30 | -$134.99M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-21 | -$134.99M derived: sum of 2 quarters · filed 2023-11-21 | $1.51M 10-Q/A · filed 2023-11-21 | $136.50M 10-Q · filed 2022-11-07 | |||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $136.50M 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | $136.50M 10-Q · filed 2023-05-15 | ||||||||
| 2021-12-31 | $54.55K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |